EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Economic Burden of Multiple Sclerosis in Slovakia

Mária Pšenková, Stanislava Mackovičová, Alexander Palúch, Tatiana Foltánová, Lenka Petrová

European Medical, Health and Pharmaceutical Journal · 2012

DOI: 10.12955/emhpj.v3i0.346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Medical, Health and Pharmaceutical Journal, 2012. Verfasst von Mária Pšenková und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The disabling nature and lifelong impact of multiple sclerosis (MS) imposes considerable socioeconomic burden despite its relative low prevalence compared to other chronic diseases. This is the first study of MS in the Slovak Republic that provides information about healthcare and social expenditures including costs of productivity loss caused by reduced work capacity of patients with MS. Retrospectively direct and indirect costs of MS were investigated by prevalence based “bottom-up” approach. The societal and health insurance perspective was used to perform the overall economic burden caused by MS in Slovakia. The human capital method was used for the calculation of indirect costs, as this is the most common method applied in published studies. As not all detailed data on expenditures were available, the missing data were collected in the retrospective patient research. Total annual costs in 2010 for 6.100 dispensed patients with MS in Slovakia were €54.723.592. Indirect costs (€31.728.757) prevailed over direct costs (€22.994.834). The highest part of both costs were €25.207.512 and €12.641.052 for loss productivity due to patients sickness and invalidity pensions and disease-modifying drugs respectively. The average cost per patient independently of disease severity was €8.971.MS causes a high economic burden, with a strong predominance of indirect costs. Documenting and quantifying this burden among patients with MS in different disease stages through cost-of-illness study can lead to better disease management and it can provide valuable information for future cost analysis and for decision-making process.

Zitieren

APA

Pšenková, M., Mackovičová, S., Palúch, A., Foltánová, T., & Petrová, L. (2012). Economic Burden of Multiple Sclerosis in Slovakia. European Medical, Health and Pharmaceutical Journal. https://doi.org/10.12955/emhpj.v3i0.346

Vancouver

Pšenková M, Mackovičová S, Palúch A, Foltánová T, Petrová L. Economic Burden of Multiple Sclerosis in Slovakia. European Medical, Health and Pharmaceutical Journal. 2012. doi:10.12955/emhpj.v3i0.346

BibTeX
@article{Penkov2012,
  author = {Pšenková, Mária and Mackovičová, Stanislava and Palúch, Alexander and Foltánová, Tatiana and Petrová, Lenka},
  title = {Economic Burden of Multiple Sclerosis in Slovakia},
  journal = {European Medical, Health and Pharmaceutical Journal},
  year = {2012},
  doi = {10.12955/emhpj.v3i0.346}
}
Kostenlos starten →